Tetra Bio Pharma Inc
TSX:TBP
Net Margin
Tetra Bio Pharma Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
|
Tetra Bio Pharma Inc
TSX:TBP
|
10.6m CAD | N/A | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
663.9B USD |
26%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
424.9B USD |
25%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
203.6B CHF |
14%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
179.8B GBP |
15%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
192.2B CHF |
25%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
36%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
211.9B USD |
26%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.9B USD |
17%
|
Tetra Bio Pharma Inc
Glance View
Tetra Bio-Pharma, Inc. engages in the discovery and development of cannabinoid-based drugs and treatments. The company is headquartered in Orleans, Ontario and currently employs 33 full-time employees. The company went IPO on 2008-04-15. The firm is engaged in the development of bio pharmaceuticals and natural health products containing cannabis and other medicinal plant-based elements. The firm is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. The firm's objective is to bring prescription drugs and treatments to relieve symptoms associated with advanced cancer pain, chronic pain, Acute Respiratory Distress Syndrom (ARDS), sepsis and ophthalmic disease. Its products include QIXLEEF, CAUMZ, REDUVO Capsules, REDUVO Adversa, ARDS-003 and PPP-002. Its QIXLEEF is a botanical inhaled drug with a fixed ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD).
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Tetra Bio Pharma Inc's most recent financial statements, the company has Net Margin of 0%.
You don't have any saved screeners yet